FMR1NB Antibody

What is FMR1NB protein and what are its known functions?

FMR1NB (FMR1 neighbor protein) is a protein-coding gene located adjacent to the FMR1 gene, which is associated with Fragile X Syndrome. FMR1NB expression has been observed preferentially in human brain tissues including the frontal cortex, whole brain, and subthalamic nucleus. Temporal expression analyses indicate that FMR1NB expression is relatively higher during the middle stages of life .

Recent research has demonstrated potential roles for FMR1NB in neurotransmitter pathways. Studies using CRISPR-mediated FMR1NB knockout mice have revealed significant differences in the expression of serotonin and dopamine metabolic pathway genes compared to wild-type mice. Specifically, four genes associated with serotonin metabolic processes (Arrb2, Cd300a, Fcgr3, and Pde1b) were upregulated in FMR1NB knockout mice . Additionally, 18 differentially expressed genes related to dopamine metabolic processes were identified, with most being upregulated in the knockout model .

FMR1NB has also been implicated in behavioral phenotypes. More specifically, FMR1NB-knockout mice demonstrated altered sexual preference behaviors, suggesting a potential role in neurobiological pathways related to behavior .

What types of FMR1NB antibodies are commercially available for research?

Commercial FMR1NB antibodies are available in several formats, with polyclonal rabbit antibodies being among the most common. For example, ab121339 is a rabbit polyclonal antibody that has been validated for multiple applications including Western blotting (WB), immunohistochemistry on paraffin-embedded tissues (IHC-P), and immunocytochemistry/immunofluorescence (ICC/IF) .

These antibodies are typically generated using recombinant fragment proteins corresponding to specific amino acid sequences within the human FMR1NB protein. For instance, ab121339 was developed using a recombinant fragment protein within the region of amino acids 50-200 of human FMR1NB .

It's important to note that these antibodies are specifically labeled as research-use-only reagents and are not approved for diagnostic or therapeutic procedures . When selecting an FMR1NB antibody, researchers should verify that the antibody has been validated for their specific application and target species.

How should researchers validate FMR1NB antibody specificity for their experiments?

Validating antibody specificity is critical for ensuring reliable experimental results. For FMR1NB antibodies, a multi-step validation approach is recommended:

• Positive and negative controls: Include known positive samples (such as testis tissue, which shows high FMR1NB expression) and appropriate negative controls. Negative controls might include vector-only transfected cell lysates as demonstrated in validation experiments for commercial antibodies .

• Knockout validation: When possible, use samples from FMR1NB knockout models as negative controls. This provides strong evidence of specificity, as any signal in knockout samples would indicate non-specific binding .

• Multiple detection methods: Validate the antibody using at least two different techniques (e.g., Western blot and immunohistochemistry) to confirm consistent results across platforms.

• Band size verification: For Western blot applications, verify that the observed band matches the predicted molecular weight of FMR1NB (approximately 29 kDa) .

• Peptide competition assay: Consider performing a peptide competition assay where the antibody is pre-incubated with the immunogen peptide before staining. Specific binding should be blocked by the peptide.

Rigorous validation is particularly important for FMR1NB antibodies since relatively limited commercial options are available, and antibody performance can vary significantly between experimental conditions.

What are the optimal protocols for using FMR1NB antibodies in Western blotting?

For optimal Western blotting results with FMR1NB antibodies, researchers should follow these methodological guidelines:

• Sample preparation: Prepare protein lysates from tissues or cells of interest using a complete lysis buffer containing protease inhibitors. For brain tissue samples, which are relevant for FMR1NB studies, special attention should be paid to rapid extraction and processing to preserve protein integrity.

• Protein loading and separation: Load 20-30 μg of total protein per lane on a 12-15% SDS-PAGE gel, as FMR1NB has a relatively low molecular weight (predicted band size: 29 kDa) .

• Transfer conditions: Use PVDF membrane and a standard wet transfer system at 100V for 1 hour or 30V overnight at 4°C for efficient transfer of the protein.

• Blocking conditions: Block the membrane with 5% non-fat dry milk in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute the FMR1NB antibody at approximately 1/250 in blocking solution and incubate overnight at 4°C . Optimization of antibody concentration may be necessary depending on the specific batch and application.

• Detection method: Use an appropriate HRP-conjugated secondary antibody and develop using enhanced chemiluminescence (ECL) technique . For low abundance targets, consider using more sensitive detection reagents or longer exposure times.

• Controls: Include a positive control (tissue known to express FMR1NB) and negative control (vector-only transfected cell lysate) in each experiment to validate results.

For researchers working with brain samples, it's important to note that FMR1NB expression varies between different brain regions. Expression level differences have been observed between intralobular white matter and cerebellar cortex (fold change = 1.2) , which may affect detection sensitivity.

What are the best practices for immunohistochemistry using FMR1NB antibodies?

For optimal immunohistochemistry results with FMR1NB antibodies, follow these best practices:

• Tissue preparation: Use properly fixed and paraffin-embedded tissues. For FMR1NB detection, testis tissue serves as an excellent positive control due to high expression levels .

• Antigen retrieval: Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) for 20 minutes, as this has been validated for FMR1NB antibodies in paraffin-embedded tissues.

• Blocking: Block endogenous peroxidase activity with 3% H₂O₂ in methanol for 15 minutes, followed by protein blocking with 5% normal serum in PBS for 1 hour.

• Primary antibody dilution: For paraffin sections, use FMR1NB antibody at a 1/50 dilution . Optimize this concentration based on your specific tissue and antibody lot.

• Incubation conditions: Incubate sections with primary antibody overnight at 4°C in a humidified chamber to maximize specific binding while minimizing background.

• Detection system: Use a polymer-based detection system rather than avidin-biotin methods to reduce background, especially in neural tissues where endogenous biotin can be problematic.

• Counterstaining: Use hematoxylin for nuclear counterstaining to provide context for FMR1NB localization.

• Controls: Include appropriate positive controls (testis tissue), negative controls (primary antibody omission), and isotype controls to ensure specificity.

When examining brain tissues, researchers should be aware that FMR1NB expression varies across different brain regions , which may result in region-specific staining patterns and intensities.

How should researchers optimize immunofluorescence protocols for FMR1NB detection?

For optimal immunofluorescence detection of FMR1NB, researchers should follow these methodological guidelines:

• Cell/tissue preparation: For cellular studies, like those conducted with U-2 OS human cell lines, proper fixation and permeabilization are critical. Use 4% paraformaldehyde (PFA) for fixation followed by permeabilization with Triton X-100 as validated for FMR1NB antibodies .

• Blocking: Block non-specific binding sites with 5% normal serum (matching the species of the secondary antibody) and 1% BSA in PBS for 1 hour at room temperature.

• Primary antibody incubation: Dilute FMR1NB antibody appropriately (optimization required for each application) and incubate overnight at 4°C. For initial testing, follow manufacturer recommendations for the specific antibody.

• Secondary antibody selection: Use highly cross-adsorbed fluorochrome-conjugated secondary antibodies to minimize cross-reactivity. Select fluorophores appropriate for your microscopy setup and experimental design.

• Nuclear counterstaining: Include DAPI or Hoechst staining to visualize nuclei, which is particularly important since FMR1NB has been observed to localize to nucleoli in certain cell types .

• Controls: Include primary antibody omission controls and positive controls to ensure specificity of staining.

• Mounting: Use anti-fade mounting media to preserve fluorescent signal during imaging and storage.

For subcellular localization studies, it's worth noting that FMR1NB has been observed in nucleoli in U-2 OS cells , suggesting nuclear or nucleolar functions that may be cell-type specific.

What considerations are important when using FMR1NB antibodies in brain tissue research?

When using FMR1NB antibodies for brain tissue research, several important considerations should be addressed:

• Regional expression variation: FMR1NB expression varies significantly across different brain regions. Research has demonstrated differential expression between intralobular white matter (WHMT) and cerebellar cortex (CRBL) (fold change = 1.2), as well as between WHMT and thalamus . These variations necessitate careful selection of brain regions for comparative studies.

• Developmental timing: The expression level of FMR1NB changes throughout the lifespan, with relatively higher expression observed during the middle stages of life . This temporal expression pattern should inform experimental design, particularly for developmental studies.

• Antigen preservation: Brain tissue is particularly susceptible to degradation. Ensure rapid fixation after tissue collection, with post-fixation times optimized for preserving FMR1NB epitopes while maintaining tissue morphology.

• Background reduction: Brain tissue often exhibits high levels of autofluorescence, particularly in aged tissues. Consider using Sudan Black B (0.1% in 70% ethanol) after secondary antibody incubation to reduce lipofuscin-related autofluorescence in immunofluorescence applications.

• Knockout validation: When possible, validate staining patterns using FMR1NB knockout tissue as a negative control. This is particularly important given the complex cellular architecture of brain tissue and potential for non-specific binding .

• Co-localization studies: Consider dual-labeling with neuronal, glial, or subcellular markers to better characterize the cell types and compartments expressing FMR1NB in the brain.

• Cross-reactivity assessment: Given the sequence similarities between FMR1 and related proteins, evaluate potential cross-reactivity with other family members, particularly in brain regions where multiple family members are expressed.

How can researchers effectively generate and validate FMR1NB knockout models?

Generating and validating FMR1NB knockout models requires careful methodological considerations:

• CRISPR-Cas9 approach: Recent research has successfully employed CRISPR-Cas9 technology to generate FMR1NB knockout mice . This approach requires:

  • Design of guide RNAs targeting conserved exons of the FMR1NB gene

  • Verification of editing efficiency in cell lines before proceeding to animal models

  • Screening of founder animals for frameshift mutations that result in functional protein loss

• Validation at the genomic level: Confirm gene disruption through:

  • PCR and sequencing of the targeted locus

  • Analysis of potential off-target effects at predicted sites

  • Verification of germline transmission in breeding studies

• Validation at the protein level: Confirm absence of FMR1NB protein through:

  • Western blot analysis using validated antibodies

  • Immunohistochemistry of tissues known to express FMR1NB (e.g., testis, specific brain regions)

  • Comparison with wild-type controls to ensure complete protein knockout

• Functional validation: Assess phenotypic changes consistent with FMR1NB loss:

  • Behavioral assessments, particularly those related to previously observed phenotypes in FMR1NB-deficient models

  • Molecular profiling of serotonin and dopamine pathway components that have shown differential expression in FMR1NB knockout models

  • Evaluation of mounting behavior and sexual preference, which have been documented to change in FMR1NB knockout mice

• Controls: Include both wild-type littermates and heterozygous animals as controls to assess gene dosage effects and distinguish between developmental and acute effects of gene loss.

Studies have shown that CRISPR-mediated FMR1NB knockout mice exhibit significant differences in sexual preference behaviors and alterations in neurotransmitter pathways compared to wild-type mice, suggesting successful functional knockout .

What techniques are recommended for studying FMR1NB-associated signaling pathways?

For investigating FMR1NB-associated signaling pathways, the following techniques are recommended:

• RNA-Seq analysis: Transcriptome profiling has been successfully employed to identify differentially expressed genes between FMR1NB knockout and wild-type mice. This approach revealed significant changes in serotonin metabolic process genes (Arrb2, Cd300a, Fcgr3, and Pde1b) and dopamine metabolic process genes (including Celsr3, Dlg4, Entpd1, among others) .

• Pathway enrichment analysis: Gene Ontology (GO) and KEGG pathway analyses of differentially expressed genes can identify enriched biological processes. Previous studies identified 21 GO terms (19 for dopamine, 4 for serotonin) and one KEGG pathway significantly enriched in FMR1NB knockout models .

• Protein-Protein Interaction (PPI) network analysis: Tools like STRING can be used to construct PPI networks of differentially expressed genes to identify key interaction nodes and potential regulatory mechanisms .

• Quantitative PCR validation: Key differentially expressed genes identified through RNA-Seq should be validated using qPCR to confirm expression changes.

• Neurotransmitter level quantification: Direct measurement of serotonin and dopamine levels in relevant brain regions using HPLC or ELISA can confirm the functional impact of gene expression changes.

• Phosphorylation state analysis: Western blotting with phospho-specific antibodies can assess activation states of key signaling molecules in serotonin and dopamine pathways.

• Electrophysiology: Patch-clamp recordings can evaluate potential changes in neuronal excitability and synaptic transmission in FMR1NB knockout models, particularly in brain regions with high FMR1NB expression.

Research has demonstrated that FMR1NB knockout alters expression in inflammation-related genes and pathways , suggesting broader effects beyond neurotransmitter systems that should be considered in experimental design.

How can researchers investigate potential interactions between FMR1 and FMR1NB?

Investigating potential interactions between FMR1 and FMR1NB requires specialized approaches that account for their genomic proximity and potential functional relationships:

• Co-immunoprecipitation (Co-IP): This technique can determine if FMR1 and FMR1NB proteins physically interact in cellular contexts:

  • Use validated antibodies against both FMR1 and FMR1NB for reciprocal Co-IP experiments

  • Include appropriate controls (IgG controls, lysates from knockout cells)

  • Verify results using both endogenous proteins and tagged constructs

• Proximity ligation assay (PLA): This method can visualize protein interactions in situ with high sensitivity:

  • Allows detection of proteins that are within 40 nm of each other

  • Particularly useful for detecting transient or weak interactions

  • Provides spatial information about where potential interactions occur within cells

• Expression correlation analysis: Evaluate whether FMR1 and FMR1NB expression levels correlate across different tissues, developmental stages, or disease states:

  • Utilize existing databases such as Human Brain Transcriptome (HBT) and BRAINEAC

  • Examine co-expression patterns in single-cell RNA-seq datasets

  • Look for coordinated expression changes in response to genetic or pharmacological perturbations

• Shared biological pathway analysis: Investigate whether FMR1 and FMR1NB participate in common biological pathways:

  • FMR1 is known to be involved in mRNA trafficking and translation regulation

  • Examine whether FMR1NB knockout affects similar processes or interacts with FMR1 targets

• Genetic interaction studies: Create double knockout/knockdown models to assess potential genetic interactions:

  • Compare phenotypes of single FMR1 knockout, single FMR1NB knockout, and double knockout models

  • Look for synergistic or antagonistic effects that would suggest functional relationships

• Chromatin organization analysis: Investigate potential co-regulation at the chromatin level:

  • Analyze chromatin conformation using Hi-C or related techniques

  • Examine whether the genes share enhancers or other regulatory elements

  • Determine if disruption of one gene affects the expression of the other

While research on direct interactions between FMR1 and FMR1NB is limited, the genomic proximity and involvement of FMR1 in RNA binding and polyribosome association suggests potential functional relationships that warrant investigation.

How should researchers interpret variable FMR1NB expression across different brain regions?

Interpreting variable FMR1NB expression across brain regions requires careful consideration of several factors:

• Quantitative assessment of regional differences: Studies have documented significant expression differences between brain regions. For example, FMR1NB transcript levels show a 1.2-fold difference between intralobular white matter (WHMT) and cerebellar cortex (CRBL) . These differences should be:

  • Quantified using multiple technical and biological replicates

  • Validated using both RNA and protein detection methods

  • Compared across developmental stages since temporal expression patterns vary

• Cellular composition considerations: Brain regions differ substantially in their cellular composition:

  • Higher expression in white matter vs. gray matter may suggest glial expression

  • Single-cell RNA sequencing data should be consulted to determine cell-type specific expression

  • Immunohistochemistry with cellular markers should be used to identify specific cell populations expressing FMR1NB

• Functional interpretation: Regional expression differences should be interpreted in the context of known regional functions:

  • Correlation with known functions of specific brain regions

  • Consideration of evolutionary conservation of expression patterns across species

  • Integration with behavioral or functional data from knockout models

• Technical validation: Verify that expression differences are not artifacts:

  • Use multiple primer sets or antibodies targeting different epitopes

  • Employ absolute quantification methods when possible

  • Include spike-in controls to normalize for technical variation

• Pathway context: Regional expression differences should be interpreted in the context of pathway activity:

  • Regions with high FMR1NB expression should be examined for differential activity in serotonin and dopamine pathways

  • Co-expression with other genes in these pathways should be assessed

Given the evidence that FMR1NB expression is temporally regulated, with higher expression in the middle stages of life , age-matched comparisons are essential when interpreting regional differences.

What statistical approaches are recommended for analyzing FMR1NB expression data?

When analyzing FMR1NB expression data, researchers should employ robust statistical approaches that account for the biological and technical variability inherent in such studies:

In previous FMR1NB studies, researchers successfully employed these approaches to identify significant differences in gene expression between knockout and wild-type mice, revealing important pathway associations with serotonin and dopamine metabolism .

How can researchers troubleshoot inconsistent results with FMR1NB antibodies?

When encountering inconsistent results with FMR1NB antibodies, researchers should implement a systematic troubleshooting approach:

• Antibody validation assessment:

  • Verify antibody specificity using positive controls (testis tissue) and negative controls (vector-only transfected lysates)

  • Test for cross-reactivity with related proteins, particularly other members of the FMR family

  • Consider using multiple antibodies targeting different epitopes of FMR1NB

• Sample preparation optimization:

  • For Western blotting: Ensure complete protein denaturation and efficient transfer of low molecular weight proteins (FMR1NB is approximately 29 kDa)

  • For IHC/IF: Optimize fixation conditions and antigen retrieval methods

  • For all applications: Include protease and phosphatase inhibitors during sample preparation

• Protocol optimization:

  • Titrate antibody concentrations to determine optimal working dilutions (e.g., 1/50 for IHC, 1/250 for Western blotting)

  • Adjust incubation times and temperatures

  • Test different blocking agents to reduce background staining

• Technical considerations:

  • For Western blotting: Ensure proper gel percentage (12-15% recommended for low molecular weight proteins)

  • For IHC: Consider different detection systems (polymer-based vs. avidin-biotin)

  • For IF: Use appropriate filters and imaging settings to minimize autofluorescence

• Biological variability assessment:

  • Consider developmental stage-dependent expression (FMR1NB shows higher expression in middle stages of life)

  • Account for regional differences in expression across brain regions

  • Note that expression may vary significantly between cell types

• Batch effects consideration:

  • Use consistent lots of antibodies when possible

  • Include internal controls across experiments

  • Process experimental and control samples simultaneously

• Method-specific troubleshooting:

  • For nucleolar staining observed in immunofluorescence : Verify specificity with appropriate controls and co-staining with nucleolar markers

  • For variable detection in brain regions: Compare with mRNA expression data from databases like HBT and BRAINEAC

By systematically addressing these factors, researchers can identify the sources of inconsistency and establish reliable protocols for FMR1NB detection across different experimental systems.